Post-COVID-19 Pulmonary Fibrosis: A Case Report and Literature Review

Yung-Hsuan Wang；Chih-Bin Lin

SARS-CoV-2 ； COVID-19 ； pulmonary fibrosis ； pirfenidone

胸腔醫學

39卷3期（2024 / 09 / 01）

262 - 266

英文

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a global pandemic in December 2019. Pulmonary fibrosis is one of the major long-term complications in patients with coronavirus-induced disease 2019 (COVID-19). There have been some ongoing clinical trials of therapies for post-COVID-19 pulmonary fibrosis. Anti-fibrotic agents such as pirfenidone and nintedanib might be potential treatment options. We reported the case of a patient with COVID-19 that developed severe pulmonary fibrosis and restrictive lung disease. Improvement of pulmonary fibrosis and lung function were noted after pirfenidone was prescribed.